Recommendations on Diagnosis, Treatment, and Monitoring for Gaucher Disease

Journal of Pediatrics

Volumn 155, Issue 4 SUPPL., 2009, Pages

  Martins, Ana Maria ^a   Valadares, Eugenia Ribeiro ^b   Porta, Gilda ^c   Coelho, Janice ^d   Filho, José Semionato ^e   Dudeque Pianovski, Mara Albonei ^f   Kerstenetzky, Marcelo Soares ^g   de Fátima Pombo Montoril, Maria ^h   Aranda, Paulo Cesar ⁱ   Pires, Ricardo Flores ^j   Mota, Ronald Moura Vale ^k   Bortolheiro, Teresa Cristina ^l  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^e Hospital da Fundação do Estado de Minas Gerais FHEMIG   (Brazil)

^f FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^g HOSPITAL DA RESTAURAÇÃO   (Brazil)

^h Fundação Centro de Hemoterapia e Hematologia do Pará HEMOPA   (Brazil)

ⁱ Hospital Evangélico de Londrina   (Brazil)

^j Clínica Dr Ricardo Pires para Doenças Metabólicas   (Brazil)

^k Hospital Socor Geral   (Brazil)

^l Serviço de Hematologia Hemoterapia da Santa Casa de São Paulo   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALGLUCERASE; ANALGESIC AGENT; BLOOD DERIVATIVE; CHITOTRIOSIDASE; GLUCOSYLCERAMIDASE; IMIGLUCERASE; MIGLUSTAT;

ARTICLE; BLOOD EXAMINATION; BONE DENSITY; BONE RADIOGRAPHY; CHRONIC LYMPHATIC LEUKEMIA; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME ACTIVITY; ENZYME REPLACEMENT; FIBROBLAST; GAUCHER DISEASE; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; LABORATORY TEST; LEUKOCYTE; LYMPHOMA; MULTIPLE MYELOMA; MUTATIONAL ANALYSIS; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PRIORITY JOURNAL; PROTHROMBIN TIME; RECOMMENDED DRUG DOSE; SPLENECTOMY; TREATMENT INDICATION;

BRAZIL; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT;

EID: 70249092205     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2009.07.004     Document Type: Article

References (84)

1. Meikle P.J., and Hopwood J.J. Lysosomal storage disorders: emerging therapeutic options require early diagnosis. Eur J Pediatr 162 Suppl 1 (2003) S34-S37
2. Grabowski G.A. Gaucher disease: lessons from a decade of therapy. J Pediatr 144 (2004) S15-S19
3. Beutler E., and Grabowski G. Gaucher Disease. In: Scriver C., Sly W., Childs B., et al. (Eds). The metabolic and molecular bases of inherited disease (2000), McGraw-Hill, New York 3663-3668
4. Nilsson O., and Svennerholm L. Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease. J Neurochem 39 (1982) 709-718
5. Schiffmann R., Heyes M.P., Aerts J.M., Dambrosia J.M., Patterson M.C., DeGraba T., et al. Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease. Ann Neurol 42 (1997) 613-621
6. Wong K., Sidransky E., Verma A., Mixon T., Sandberg G.D., Wakefield L.K., et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 82 (2004) 192-207
7. Barranger J., and Rice O. Gaucher disease: diagnosis, monitoring, and management. Gaucher Clin Perspect 5 (1997) 1-6
8. Grabowski G.A., Leslie N., and Wenstrup R. Enzyme therapy for Gaucher disease: the first 5 years. Blood Rev 12 (1998) 115-133
9. Incerti C. Gaucher disease: an overview. Semin Hematol 32 (1995) 3
10. Charrow J., Esplin J.A., Gribble T.J., Kaplan P., Kolodny E.H., Pastores G.M., et al. Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med 158 (1998) 1754-1760
11. Weinreb N.J., Aggio M.C., Andersson H.C., Andria G., Charrow J., Clarke J.T., et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 41 (2004) 15-22
12. Charrow J., Andersson H.C., Kaplan P., Kolodny E.H., Mistry P., Pastores G., et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 144 (2004) 112-120
13. Andersson H.C., Charrow J., Kaplan P., Mistry P., Pastores G.M., Prakash-Cheng A., et al. Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med 7 (2005) 105-110
14. vom Dahl S., Poll L., Di Rocco M., Ciana G., Denes C., Mariani G., and Maas M. Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients. Curr Med Res Opin 22 (2006) 1045-1064
15. Martins A.M., Lobo C.L., Sobreira E.A.P., et al. Tratamento da doença de Gaucher: um consenso brasileiro. Rev Bras Hematol Hemoter 25 (2003) 89-95
16. Sidransky E. Gaucher disease: complexity in a "simple" disorder. Mol Genet Metab 83 (2004) 6-15
17. Altarescu G., Schiffmann R., Parker C.C., Moore D.F., Kreps C., Brady R.O., et al. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease. Blood Cells Mol Dis 26 (2000) 285-290
18. Gaucher disease. Current issues in diagnosis and treatment. NIH Technology Assessment Panel on Gaucher Disease. JAMA 275 (1996) 548-553
19. Zimran A., Gelbart T., Westwood B., Grabowski G.A., and Beutler E. High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews. Am J Hum Genet 49 (1991) 855-859
20. Hollak C.E., Levi M., Berends F., Aerts J.M., and van Oers M.H. Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. Br J Haematol 96 (1997) 470-476
21. Charrow J., Andersson H.C., Kaplan P., Kolodny E.H., Mistry P., Pastores G., et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 160 (2000) 2835-2843
22. Weinreb N.J., Charrow J., Andersson H.C., Kaplan P., Kolodny E.H., Mistry P., et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 113 (2002) 112-119
23. McHugh K., and Olsen ØE V.A. Gaucher disease in children: radiology of non-central nervous system manifestations. Clin Radiol 59 (2004) 117-123
24. Barranger J.A., and O'Rourke E. Lessons learned from the development of enzyme therapy for Gaucher disease. J Inherit Metab Dis 24 Suppl 2 (2001) 89-96 discussion 87-8
25. Weinreb N., and Lee R. Changing patterns of mortality in Gaucher disease prior to and following the advent of enzyme replacement therapy. Blood 11 (2004) Abstract 3799
26. Mignot C., Doummar D., Maire I., and De Villemeur T.B. Type 2 Gaucher disease: 15 new cases and review of the literature. Brain Dev 28 (2006) 39-48
27. Sidransky E., Fartasch M., Lee R.E., Metlay L.A., Abella S., Zimran A., et al. Epidermal abnormalities may distinguish type 2 from type 1 and type 3 of Gaucher disease. Pediatr Res 39 (1996) 134-141
28. Stone D.L., van Diggelen O.P., de Klerk J.B., Gaillard J.L., Niermeijer M.F., Willemsen R., et al. Is the perinatal lethal form of Gaucher disease more common than classic type 2 Gaucher disease?. Eur J Hum Genet 7 (1999) 505-509
29. Vellodi A., Bembi B., de Villemeur T.B., Collin-Histed T., Erikson A., Mengel E., et al. Management of neuronopathic Gaucher disease: a European consensus. J Inherit Metab Dis 24 (2001) 319-327
30. Altarescu G., Hill S., Wiggs E., Jeffries N., Kreps C., Parker C.C., et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J Pediatr 138 (2001) 539-547
31. Sirrs S., Irving J., McCauley G., Gin K., Munt B., Pastores G., et al. Failure of resting echocardiography and cardiac catheterization to identify pulmonary hypertension in two patients with type I Gaucher disease. J Inherit Metab Dis 25 (2002) 131-132
32. Esplin J. Overview: Gaucher disease. Gaucher Clin Perspect 2 (1994) 1-5
33. Barranger J., and Rice E. An overview of Gaucher disease. Gaucher Clin Perspect 1 (1993) 1-5
34. James S.P., Stromeyer F.W., Chang C., and Barranger J.A. Liver abnormalities in patients with Gaucher's disease. Gastroenterology 80 (1981) 126-133
35. Lee R. The pathology of Gaucher disease. In: Desnick R. (Ed). Gaucher disease a century of delineation and research (1982), John Wiley & Sons, Baltimore 177-217
36. Platzker Y., Fisman E.Z., Pines A., and Kellermann J.J. Unusual echocardiographic pattern in Gaucher's disease. Cardiology 72 (1985) 144-146
37. Torloni M.R., Franco K., and Sass N. Gaucher's disease with myocardial involvement in pregnancy. Sao Paulo Med J 120 (2002) 90-92
38. Hollak C. Renal involvement in type 1 Gaucher disease. Gaucher Clin Perspect 6 (1998) 14-15
39. Santoro D., Rosenbloom B.E., and Cohen A.H. Gaucher disease with nephrotic syndrome: response to enzyme replacement therapy. Am J Kidney Dis 40 (2002) E4
40. Clarke J. Gaucher disease: differential diagnosis. Gaucher Clin Perspect 5 (1997) 6-12
41. Lewin A., Orvisky E., Goker-Alpan O., LaMarca M.E., and Sidransky E. Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab 81 (2004) 70-73
42. Tayebi N., Callahan M., Madike V., Stubblefield B.K., Orvisky E., Krasnewich D., et al. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 73 (2001) 313-321
43. Rosenbloom B.E., Weinreb N.J., Zimran A., Kacena K.A., Charrow J., and Ward E. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 105 (2005) 4569-4572
44. Costello R., O'Callaghan T., and Sébahoun G. Gaucher disease and multiple myeloma. Leuk Lymphoma 47 (2006) 1365-1368
45. Landgren O., Turesson I., Gridley G., and Caporaso N.E. Risk of malignant disease among 1525 adult male US Veterans with Gaucher disease. Arch Intern Med 167 (2007) 1189-1194
46. Cheung W.Y., Greenberg C.R., Bernstein K., Schacter B., Fourie T., and Seftel M.D. Type I Gaucher disease following chemotherapy for light chain multiple myeloma. Intern Med 46 (2007) 1255-1258
47. Hughes D., Cappellini M.D., Berger M., Droogenbroeck J.V., De Fost M., Janic D., et al. Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol 138 (2007) 676-686
48. Michelin K., Wajner A., Goulart Lda S., Fachel A.A., Pereira M.L., de Mello A.S., et al. Biochemical study on beta-glucosidase in individuals with Gaucher's disease and normal subjects. Clin Chim Acta 343 (2004) 145-153
49. Hollak C.E., van Weely S., van Oers M.H., and Aerts J.M. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93 (1994) 1288-1292
50. Cabrera-Salazar M.A., O'Rourke E., Henderson N., Wessel H., and Barranger J.A. Correlation of surrogate markers of Gaucher disease. Implications for long-term follow up of enzyme replacement therapy. Clin Chim Acta 344 (2004) 101-107
51. Sobreira E., Pires R.F., Cizmarik M., and Grabowski G.A. Phenotypic and genotypic heterogeneity in Gaucher disease type 1: A comparison between Brazil and the rest-of-the-world. Mol Genet Metab 90 (2007) 81-86
52. Kolodny E., and Tenembaum L. Storage diseases of the reticuloendothelial system. In: Nathan D., and Oski F. (Eds). Hematology of infancy and childhood (1992), WB Saunders, Philadelphia 1452-1491
53. Pentchev P., Vanier M., Suzuki K., and Patterson M. Niemann-Pick disease type C: a cellular cholesterol lipidosis. In: Scriver C., Beaudet A., Sly W., and Valle D. (Eds). The metabolic and molecular basis of inherited disease (1995), McGraw-Hill, New York 2625-2639
54. Schuchman E., and Desnick R. Niemann-Pick disease types A and B: acid sphingomyelinase deficiencies. In: Scriver C., Beaudet A., Sly W., and Valle D. (Eds). The metabolic and molecular basis of inherited disease (1995), McGraw-Hill, New York 2601-2604
55. Gillis S., Hyam E., Abrahamov A., Elstein D., and Zimran A. Platelet function abnormalities in Gaucher disease patients. Am J Hematol 61 (1999) 103-106
56. Hermann G., Pastores G.M., Abdelwahab I.F., and Lorberboym A.M. Gaucher disease: assessment of skeletal involvement and therapeutic responses to enzyme replacement. Skeletal Radiol 26 (1997) 687-696
57. Pastores G.M., Wallenstein S., Desnick R.J., and Luckey M.M. Bone density in type 1 Gaucher disease. J Bone Miner Res 11 (1996) 1801-1807
58. Lutsky K.F., and Tejwani N.C. Orthopaedic manifestations of Gaucher disease. Bull NYU Hosp Jt Dis 65 (2007) 37-42
59. Mistry P.K., Sirrs S., Chan A., Pritzker M.R., Duffy T.P., Grace M.E., et al. Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Gente Metab 77 (2002) 91-98
60. Starzyk K., Richards S., Yee J., Smith S.E., and Kingman W. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet Metab 90 (2007) 157-163
61. European Medicines Agengy. Zavesca. European Public Assessment Report. Disponível em: www.emea.eu.int/humandocs/Humans/EPAR/zavesca/zavesca.htm. Accessed: Oct. 8, 2006.
62. Weinreb N.J., Barranger J.A., Charrow J., Grabowski G.A., Mankin H.J., and Mistry P. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol 80 (2005) 223-229
63. Kuczmarski R.J., Ogden C.L., Guo S.S., et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 (2002) 1-190
64. Damiano A.M., Pastores G.M., and Ware Jr. J.E. The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study. Qual Life Res 7 (1998) 373-386
65. Masek B.J., Sims K.B., Bove C.M., Korson M.S., Short P., and Norman D.K. Quality of life assessment in adults with type 1 Gaucher disease. Qual Life Res 8 (1999) 263-268
66. Schmitz J., Poll L.W., and Dahl S.V. Therapy of adult Gaucher disease. Haematologica 92 (2007) 148-152
67. Wenstrup R.J., Kacena K.A., Kaplan P., Pastores G.M., Prakash-Cheng A., Zimran A., et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res 22 (2007) 119-126
68. Charrow J., Dulisse B., Grabowski G.A., and Weinreb N.J. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gauchewr disease. Clin Genet 71 (2007) 205-211
69. Weinreb N., Barranger J., Packman S., Prakash-Cheng A., Rosenbloom B., Sims K., et al. Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet 71 (2007) 576-588
70. De Fost M., Hollak C.E.M., Groener J.E.M., Aerts J.M.F.G., Maas M., Poll L.W., et al. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood 108 (2006) 830-835
71. Brady R.O., Kanfer J.N., and Shapiro D. Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease. Biochem Biophys Res Commun 18 (1965) 221-225
72. Bembi B., Ciana G., Mengel E., Terk M.R., Martini C., and Wenstrup R.J. Bone complications in children with Gaucher disease. Br J Radiol 75 Suppl 1 (2002) A37-A44
73. Kaplan P., Mazur A., Manor O., Charrow J., Esplin J., Gribble T.J., et al. Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. J Pediatr 129 (1996) 149-153
74. Drelichman G., Ponce E., Basack N., Freigeiro D., Aversa L., Graciela E., et al. Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease. J Pediatr 15 (2007) 197-201
75. Pastores G.M., Winreb N.J., Aerts H., Andria G., Cox T.M., Giralt M., et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 41 Suppl 5 (2004) 4-14
76. Rosenthal D.I., Doppelt S.H., Mankin H.J., Dambrosia J.M., Xavier R.J., McKusick K.A., et al. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 96 (1995) 629-637
77. Kolodny EH. Comunicação Pessoal, 6th International Postgraduate Course on Lysossomal Storage Diseases, Nierstein-Mainz-Germany, June 10-15, 2007.
78. Grabowski, GA. Comunicação Pessoal, 1o Encontro Brasileiro do GBDDL-Atualização Terapêutica, Rio de Janeiro-RJ-Brasil, 9-11 de Agosto, 2007.
79. de Fost M., Hollak C.E., Groener J.E., Aerts J.M., Maas M., Poll L.W., et al. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood 108 (2006) 830-835
80. Altarescu G., Schiffmann R., Parker C.C., Moore D.F., Kreps C., Brady R.O., et al. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease. Blood Cells Mol Dis 26 (2000) 285-290
81. de Fost M., Aerts J.M.F.G., Groener J.E.M., Maas M., Akkerman E.M., Wiersma M.G., et al. Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica 92 (2007) 215-221
82. Mota R.M., and Mankin H. Use of plain radiography to optimize skeletal outcomes in children with type 1 Gaucher disease in Brazil. J Pediatr Orthop 27 (2007) 347-350
83. Czartoryska B., Tylki-Szymanska A., and Lugowska A. Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease. Clin Biochem 33 (2000) 147-149
84. Maas M., Hangartner T., Mariani G., McHugh K., Moore S., Grabowski G.A., et al. Recommendations for the assessment and monitoring of skeletal manifestations in children with Guacher disease. Skeletal Radiol 37 (2008) 185-188